|
| Press Releases |
|
 |
|
| Tuesday, December 15, 2020 |
|
|
德琪醫藥中長線價值俱佳 未來兩年陸續收成 |
| 中國生物科技股行業前景佳,市場對創新醫藥的需求隨著醫療服務質量的持續提升而擴大,尤其在抗腫瘤及免疫系統相關治療領域,未來市場新增需求更有望迎來黃金機遇。 more info >> |
|
| Friday, November 20, 2020 |
|
|
覆蓋亞太地區的一體化創新腫瘤藥公司德琪醫藥有限公司於香港聯合交易所主板掛牌 |
| 德琪醫藥有限公司(「德琪醫藥」或「公司」,連同其附屬公司,統稱「集團」;股份代號:6996.HK),一家面向亞太、佈局全球,集新藥開發、臨床研究於一體的臨床階段生物醫藥公司,今天於香港聯合交易所有限公司(「港交所」)主板正式掛牌並開始交易。 more info >> |
|
|
Antengene Corporation Successfully Listed on Main Board of SEHK |
| Antengene Corporation Limited ("Antengene" or the "Company", together with its subsidiaries, the "Group", stock code: 6996.HK), a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today. more info >> |
|
| Monday, July 20, 2020 |
|
|
德琪醫藥C輪融資9700萬美元,主要用於新藥研發和商業化 |
| 專注於研發和商業化腫瘤領域全新機制及同類最優創新藥的領導企業——德琪醫藥,今日宣佈完成9700萬美元C輪融資。 more info >> |
|
|
德琪医药C轮融资9700万美元,主要用于新药研发和商业化 |
| 专注于研发和商业化肿瘤领域全新机制及同类最优创新药的领导企业——德琪医药,今日宣布完成9700万美元C轮融资。 more info >> |
|
|
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization |
| Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, today announced that it has successfully closed US$97 million in Series C financing. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00: JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00 HKT/SGT
|
|
|
HKTDC's response to World Trade Organization's latest report
Apr 3, 2026 23:00 HKT/SGT
|
|
|
海通恒信2025年報:協同效應加速釋放 新興賽道引領結構升級
Apr 3, 2026 20:28 HKT/SGT
|
|
|
海通恒信2025年报:协同效应加速释放 新兴赛道引领结构升级
Apr 3, 2026 19:43 HKT/SGT
|
|
|
HKTDC's response to World Trade Organization's latest report
Apr 3, 2026 17:11: JST
|
|
|
新希望乳業攜手香港十字牌 借道本土老字號共拓港澳市場
Apr 3, 2026 16:51 HKT/SGT
|
|
|
新希望乳业携手香港十字牌 借道本土老字号共拓港澳市场
Apr 3, 2026 16:44 HKT/SGT
|
|
|
新希望乳業與香港十字牌達成戰略合作:雙方充分發揮資源稟賦 助力港澳乳品行業高質量發展
Apr 3, 2026 16:38 HKT/SGT
|
|
|
新希望乳业与香港十字牌达成战略合作:双方充分发挥资源禀赋 助力港澳乳品行业高质量发展
Apr 3, 2026 16:26 HKT/SGT
|
|
|
マツダ、2026年度の参加型モータースポーツ活動計画を発表
Apr 3, 2026 12:00: JST
|
|
|
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Apr 3, 2026 12:33 JST
|
|
|
Hitachi Rail announces agreement to acquire Clever Devices, marking its growth as a global digital mobility player
Apr 3, 2026 11:09 JST
|
|
|
Datavault AI 執行長納撒尼爾·布拉德利將於 XRP Tokyo 2026 大會上介紹 DataValue(R)、DataScore(R) 及 Information Data Exchange(R) 技術
Apr 3, 2026 07:00 HKT/SGT
|
|
|
Datavault AI 首席执行官纳撒尼尔·布拉德利将在 XRP 东京 2026 大会上介绍 DataValue(R)、DataScore(R) 和 Information Data Exchange(R) 技术
Apr 3, 2026 07:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|